ADC Therapeutics (ADCT) Stock Price, Quote, News & History | Benzinga

SPY777.29−0.16%QQQ743.86−0.99%BTC/USD83,737.84+2.45%DIA518.08+0.38%GLD382.24−0.61%TLT77.97−0.01%

ADC Therapeutics SA (ADCT) Stock Price, Quote, News & History

ADCTNYSE

Trade with Public

Trade with Public

$1.86

0.147.8%

Last update: Oct 12, 7:39 PM

$1.85

0.126.94%

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$1.70

Close

$1.87

Volume / Avg.

1.59M / 1.46M

Day Range

$1.85 - $1.85

52 Wk Range

0.78 - 4.98

Market Cap

$237.46M

P/E Ratio

-

Dividend Yield

-

Exchange

NYSE

RSI

80

Short Interest

6.37%

Days to Cover

4.37

Recent Adc Therapeutics Ltd News

These 7 Small Caps Are on Fire as the Second Half Begins: Here’s Why

Seven small-cap stocks have surged as much as 123% in early July on buyouts, FDA developments, refinancing deals and short squeezes.

Piero Cingari

This ADC Therapeutics Analyst Is No Longer Bullish; Here Are Top 2 Downgrades For Monday

Top Wall Street analysts changed outlook on top names. ADCT downgraded See analysts' views.

Avi Kapoor

ADC Therapeutics Tumbles On Phase 3 Trial Safety Concerns, Joins Other Big Stocks Moving Lower In Thursday's Pre-Market Session (CORRECTED)

U.S. stock futures down on tech profit-taking and weak guidance, ADC Therapeutics shares plunge 50.67%, other stocks also slide.

Avi Kapoor

Why Is ADC Therapeutics Stock Falling On Friday?

Discover why ADC Therapeutics (NYSE:ADCT) stock is tumbling on Friday as a prominent Wall Street analyst slashes targets due to serious trial safety signals.

Kaustubh Bagalkote

Why Is ADC Therapeutics Stock Falling Thursday?

ADC Therapeutics stock plunges premarket as LOTIS-3 trial shows elevated serious, Grade 5 adverse events despite meeting its primary endpoint.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-102.27M

Investing Cash Flow (TTM)

627.00K

Financing Cash Flow (TTM)

56.21M

Free Cash Flow (TTM)

-102.30M

Capital Expenditure (TTM)

-32.00K

Net Change in Cash (TTM)

-45.43M

Analyst Trends and Forecast

2

May

1

Jun

1

Aug

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.3

Hold

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$119.32M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

3.48

PB Ratio (TTM)

-

Earnings Yield % (TTM)

-31.18%

Earnings Yield % (FWD)

-30.11%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

-$1.79

Company Debt

Total Debt

$116.62M

LT Debt

$110.44M

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$219.11M

Debt to Equity

-

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-